Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
44.04
-0.11 (-0.25%)
At close: Jan 9, 2026, 4:00 PM EST
44.13
+0.09 (0.21%)
After-hours: Jan 9, 2026, 7:30 PM EST
Exelixis Employees
Exelixis had 1,147 employees as of December 31, 2024. The number of employees decreased by 163 or -12.44% compared to the previous year.
Employees
1,147
Change (1Y)
-163
Growth (1Y)
-12.44%
Revenue / Employee
$1,994,959
Profits / Employee
$591,023
Market Cap
11.86B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,147 | -163 | -12.44% |
| Dec 31, 2023 | 1,310 | 87 | 7.11% |
| Dec 31, 2022 | 1,223 | 269 | 28.20% |
| Dec 31, 2021 | 954 | 181 | 23.42% |
| Dec 31, 2020 | 773 | 156 | 25.28% |
| Dec 31, 2019 | 617 | 133 | 27.48% |
| Dec 31, 2018 | 484 | 112 | 30.11% |
| Dec 31, 2017 | 372 | 85 | 29.62% |
| Dec 31, 2016 | 287 | 172 | 149.57% |
| Dec 31, 2015 | 115 | 17 | 17.35% |
| Dec 31, 2014 | 98 | -129 | -56.83% |
| Dec 31, 2013 | 227 | 53 | 30.46% |
| Dec 31, 2012 | 174 | -26 | -13.00% |
| Dec 31, 2011 | 200 | -183 | -47.78% |
| Dec 31, 2010 | 383 | -293 | -43.34% |
| Dec 31, 2009 | 676 | 0 | - |
| Dec 31, 2008 | 676 | -59 | -8.03% |
| Dec 31, 2007 | 735 | 84 | 12.90% |
| Dec 31, 2006 | 651 | 101 | 18.36% |
| Dec 31, 2005 | 550 | 33 | 6.38% |
| Dec 31, 2004 | 517 | -56 | -9.77% |
| Dec 31, 2003 | 573 | 23 | 4.18% |
| Dec 31, 2002 | 550 | -21 | -3.68% |
| Dec 31, 2001 | 571 | 214 | 59.94% |
| Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EXEL News
- 2 days ago - Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Business Wire
- 3 days ago - Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - Business Wire
- 9 days ago - See How Rare Bullish Inflows Lift Outliers Like Exelixis - FXEmpire
- 4 weeks ago - Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript - Seeking Alpha
- 5 weeks ago - Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 - Business Wire
- 2 months ago - Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 2 months ago - Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still - Seeking Alpha
- 2 months ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November - Business Wire